CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
具有抗白血病与抗淋巴瘤活性的天然产物最新进展
英文原题：Recent Advances in Natural Products with Anti-Leukemia and Anti- Lymphoma Activities.
查看英文原题
Recent Advances in Natural Products with Anti-Leukemia and Anti- Lymphoma Activities.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
白血病和淋巴瘤是最常见的血液癌症，对成人和儿童健康均构成重大威胁，全球二者总发病率和死亡率约为6%。与费用昂贵的CAR-T 细胞疗法相比，来自动物、植物和微生物的天然产物来源广泛、成本效益较好，可用于癌症治疗。此外，白血病和淋巴瘤治疗中出现的耐药现象，迫切要求开发新药。除了已上市用于治疗白血病和淋巴瘤的天然产物外，近年来也有大量研究探索对抗血液肿瘤的天然产物。本文综述近期具有抗淋巴瘤和抗白血病活性的天然化合物研究，希望为药物研发提供新的候选资源。
展开英文摘要原文
Leukemia and lymphoma are the most common blood cancers, which pose a critical threat to the health of adults and children. The total incidence and mortality rates of both are approximately 6% globally. Compared with the expensive cost of CAR T cell therapy, natural products from animals, plants and microorganisms have the characteristics of wide-range sources and costeffectiveness in the treatment of cancer.
Moreover, the drug resistance that emerged in leukemia and lymphoma treatments shows an urgent need for new drugs.
However, in addition to the natural products that have been marketed in the treatment of leukemia and lymphoma, there have been a large number of studies on natural products that fight blood cancer in recent years. This review summarized the recent studies on natural compounds with anti-lymphoma and anti-leukemia activities, hoping to provide novel weapons into the drug development arsenal.
论文信息
- 作者
- Sun ZG、Yao CJ、Ullah I、Zhu HL
- 第一作者单位
- Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi, 276400, China.China
- 通讯作者单位
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Road, Nanjing, 210023, China.China
- 文献类型
- 综述
- 期刊
- Mini reviews in medicinal chemistry2024
- 原文标识
- PubMed 37855279 · DOI 10.2174/0113895575258798230927061557